Chargement en cours...

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

OBJECTIVE: Sucroferric oxyhydroxide, a novel iron-based phosphate-binder, has been shown to have beneficial effects in lowering serum phosphorus levels and improving renal anemia in clinical studies. Although an effect of this agent on fibroblast growth factor 23 (FGF23) has been reported in an anim...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Res Notes
Auteurs principaux: Shima, Hisato, Miya, Keiko, Okada, Kazuyoshi, Minakuchi, Jun, Kawashima, Shu
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5994086/
https://ncbi.nlm.nih.gov/pubmed/29884226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-018-3483-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!